Trevena, Inc.
Trevena, Inc. (TRVN) Stock Competitors & Peer Comparison
See (TRVN) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TRVN | $0.00 | -90.99% | 864 | N/A | -$48.89 | N/A |
| NVO | $45.60 | +2.35% | 202.2B | 10.66 | $4.27 | +3.93% |
| VRTX | $447.25 | +2.29% | 113.7B | 26.55 | $16.87 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $616.30 | -1.82% | 64B | 15.18 | $40.95 | +0.58% |
| ARGX | $834.68 | +1.71% | 51.9B | 37.27 | $22.50 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $300.00 | +1.48% | 40.7B | 76.46 | $3.99 | N/A |
| RVMD | $155.89 | +1.89% | 32.9B | -21.77 | -$7.11 | N/A |
| UTHR | $548.79 | -3.85% | 23.9B | 20.79 | $27.04 | N/A |
Stock Comparison
TRVN vs NVO Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, NVO has a market cap of 202.2B. Regarding current trading prices, TRVN is priced at $0.00, while NVO trades at $45.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas NVO's P/E ratio is 10.66. In terms of profitability, TRVN's ROE is -10.15%, compared to NVO's ROE of +0.66%. Regarding short-term risk, TRVN is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check NVO's competition here
TRVN vs VRTX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, VRTX has a market cap of 113.7B. Regarding current trading prices, TRVN is priced at $0.00, while VRTX trades at $447.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is 26.55. In terms of profitability, TRVN's ROE is -10.15%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, TRVN is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check VRTX's competition here
TRVN vs VRNA Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, TRVN is priced at $0.00, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -102.80. In terms of profitability, TRVN's ROE is -10.15%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, TRVN and VRNA have similar daily volatility (0.00).Check VRNA's competition here
TRVN vs REGN Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, REGN has a market cap of 64B. Regarding current trading prices, TRVN is priced at $0.00, while REGN trades at $616.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 15.18. In terms of profitability, TRVN's ROE is -10.15%, compared to REGN's ROE of +0.14%. Regarding short-term risk, TRVN is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check REGN's competition here
TRVN vs ARGX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, ARGX has a market cap of 51.9B. Regarding current trading prices, TRVN is priced at $0.00, while ARGX trades at $834.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 37.27. In terms of profitability, TRVN's ROE is -10.15%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, TRVN is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check ARGX's competition here
TRVN vs SGEN Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, TRVN is priced at $0.00, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, TRVN's ROE is -10.15%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, TRVN is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check SGEN's competition here
TRVN vs ALNY Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, ALNY has a market cap of 40.7B. Regarding current trading prices, TRVN is priced at $0.00, while ALNY trades at $300.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is 76.46. In terms of profitability, TRVN's ROE is -10.15%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, TRVN is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check ALNY's competition here
TRVN vs RVMD Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, RVMD has a market cap of 32.9B. Regarding current trading prices, TRVN is priced at $0.00, while RVMD trades at $155.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -21.77. In terms of profitability, TRVN's ROE is -10.15%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, TRVN is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check RVMD's competition here
TRVN vs UTHR Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, UTHR has a market cap of 23.9B. Regarding current trading prices, TRVN is priced at $0.00, while UTHR trades at $548.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 20.79. In terms of profitability, TRVN's ROE is -10.15%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, TRVN is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check UTHR's competition here
TRVN vs BNTX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, BNTX has a market cap of 23.6B. Regarding current trading prices, TRVN is priced at $0.00, while BNTX trades at $96.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -15.84. In terms of profitability, TRVN's ROE is -10.15%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, TRVN is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check BNTX's competition here
TRVN vs INSM Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, INSM has a market cap of 23.5B. Regarding current trading prices, TRVN is priced at $0.00, while INSM trades at $107.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas INSM's P/E ratio is -18.81. In terms of profitability, TRVN's ROE is -10.15%, compared to INSM's ROE of -1.30%. Regarding short-term risk, TRVN is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check INSM's competition here
TRVN vs RPRX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, RPRX has a market cap of 23.4B. Regarding current trading prices, TRVN is priced at $0.00, while RPRX trades at $54.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 28.67. In terms of profitability, TRVN's ROE is -10.15%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, TRVN is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check RPRX's competition here
TRVN vs ROIV Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, ROIV has a market cap of 21.5B. Regarding current trading prices, TRVN is priced at $0.00, while ROIV trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -55.35. In terms of profitability, TRVN's ROE is -10.15%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, TRVN is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check ROIV's competition here
TRVN vs BGNE Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, TRVN is priced at $0.00, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, TRVN's ROE is -10.15%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, TRVN is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check BGNE's competition here
TRVN vs INCY Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, INCY has a market cap of 19.5B. Regarding current trading prices, TRVN is priced at $0.00, while INCY trades at $97.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 13.77. In terms of profitability, TRVN's ROE is -10.15%, compared to INCY's ROE of +0.29%. Regarding short-term risk, TRVN is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check INCY's competition here
TRVN vs MRNA Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, MRNA has a market cap of 18.9B. Regarding current trading prices, TRVN is priced at $0.00, while MRNA trades at $48.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -5.84. In terms of profitability, TRVN's ROE is -10.15%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, TRVN is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check MRNA's competition here
TRVN vs DNA-WT Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, TRVN is priced at $0.00, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, TRVN's ROE is -10.15%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, TRVN is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check DNA-WT's competition here
TRVN vs GMAB Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, GMAB has a market cap of 16.6B. Regarding current trading prices, TRVN is priced at $0.00, while GMAB trades at $26.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 20.48. In terms of profitability, TRVN's ROE is -10.15%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, TRVN is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check GMAB's competition here
TRVN vs NBIX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, NBIX has a market cap of 15.7B. Regarding current trading prices, TRVN is priced at $0.00, while NBIX trades at $158.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas NBIX's P/E ratio is 24.06. In terms of profitability, TRVN's ROE is -10.15%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, TRVN is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check NBIX's competition here
TRVN vs JAZZ Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, JAZZ has a market cap of 14.8B. Regarding current trading prices, TRVN is priced at $0.00, while JAZZ trades at $232.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is 1961.50. In terms of profitability, TRVN's ROE is -10.15%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, TRVN is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check JAZZ's competition here
TRVN vs ASND Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, TRVN is priced at $0.00, while ASND trades at $222.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas ASND's P/E ratio is 27.02. In terms of profitability, TRVN's ROE is -10.15%, compared to ASND's ROE of -56.42%. Regarding short-term risk, TRVN is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check ASND's competition here
TRVN vs SMMT Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, SMMT has a market cap of 13.5B. Regarding current trading prices, TRVN is priced at $0.00, while SMMT trades at $18.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -10.95. In terms of profitability, TRVN's ROE is -10.15%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, TRVN is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check SMMT's competition here
TRVN vs BBIO Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, BBIO has a market cap of 13.4B. Regarding current trading prices, TRVN is priced at $0.00, while BBIO trades at $67.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -18.30. In terms of profitability, TRVN's ROE is -10.15%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, TRVN is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check BBIO's competition here
TRVN vs EXEL Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, EXEL has a market cap of 12.9B. Regarding current trading prices, TRVN is priced at $0.00, while EXEL trades at $51.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 17.04. In terms of profitability, TRVN's ROE is -10.15%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, TRVN is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check EXEL's competition here
TRVN vs IONS Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, IONS has a market cap of 12.8B. Regarding current trading prices, TRVN is priced at $0.00, while IONS trades at $77.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -38.47. In terms of profitability, TRVN's ROE is -10.15%, compared to IONS's ROE of -0.59%. Regarding short-term risk, TRVN is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check IONS's competition here
TRVN vs KRTX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, TRVN is priced at $0.00, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, TRVN's ROE is -10.15%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, TRVN is less volatile compared to KRTX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check KRTX's competition here
TRVN vs AXSM Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, AXSM has a market cap of 12B. Regarding current trading prices, TRVN is priced at $0.00, while AXSM trades at $233.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -62.59. In terms of profitability, TRVN's ROE is -10.15%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, TRVN is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check AXSM's competition here
TRVN vs MDGL Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, TRVN is priced at $0.00, while MDGL trades at $498.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -38.19. In terms of profitability, TRVN's ROE is -10.15%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, TRVN is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check MDGL's competition here
TRVN vs RNAM Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, TRVN is priced at $0.00, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas RNAM's P/E ratio is -17.39. In terms of profitability, TRVN's ROE is -10.15%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, TRVN and RNAM have similar daily volatility (0.00).Check RNAM's competition here
TRVN vs ARWR Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, ARWR has a market cap of 11.1B. Regarding current trading prices, TRVN is priced at $0.00, while ARWR trades at $77.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -34.82. In terms of profitability, TRVN's ROE is -10.15%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, TRVN is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check ARWR's competition here
TRVN vs BMRN Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, BMRN has a market cap of 10.2B. Regarding current trading prices, TRVN is priced at $0.00, while BMRN trades at $55.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 37.94. In terms of profitability, TRVN's ROE is -10.15%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, TRVN is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check BMRN's competition here
TRVN vs RXDX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, TRVN is priced at $0.00, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, TRVN's ROE is -10.15%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, TRVN is less volatile compared to RXDX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check RXDX's competition here
TRVN vs CYTK Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, TRVN is priced at $0.00, while CYTK trades at $76.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -11.21. In terms of profitability, TRVN's ROE is -10.15%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, TRVN is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check CYTK's competition here
TRVN vs KRYS Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, KRYS has a market cap of 9.1B. Regarding current trading prices, TRVN is priced at $0.00, while KRYS trades at $308.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 41.43. In terms of profitability, TRVN's ROE is -10.15%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, TRVN is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check KRYS's competition here
TRVN vs IMGN Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, TRVN is priced at $0.00, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, TRVN's ROE is -10.15%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, TRVN is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check IMGN's competition here
TRVN vs ABVX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, ABVX has a market cap of 8.5B. Regarding current trading prices, TRVN is priced at $0.00, while ABVX trades at $132.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas ABVX's P/E ratio is -24.16. In terms of profitability, TRVN's ROE is -10.15%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, TRVN is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check ABVX's competition here
TRVN vs BPMC Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, TRVN is priced at $0.00, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.58. In terms of profitability, TRVN's ROE is -10.15%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, TRVN and BPMC have similar daily volatility (0.00).Check BPMC's competition here
TRVN vs CERE Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, TRVN is priced at $0.00, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, TRVN's ROE is -10.15%, compared to CERE's ROE of -0.72%. Regarding short-term risk, TRVN is less volatile compared to CERE. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check CERE's competition here
TRVN vs HALO Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, TRVN is priced at $0.00, while HALO trades at $67.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 23.92. In terms of profitability, TRVN's ROE is -10.15%, compared to HALO's ROE of +1.26%. Regarding short-term risk, TRVN is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check HALO's competition here
TRVN vs IBRX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, IBRX has a market cap of 8.1B. Regarding current trading prices, TRVN is priced at $0.00, while IBRX trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -9.08. In terms of profitability, TRVN's ROE is -10.15%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, TRVN is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check IBRX's competition here
TRVN vs NUVL Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, NUVL has a market cap of 8B. Regarding current trading prices, TRVN is priced at $0.00, while NUVL trades at $110.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -18.03. In terms of profitability, TRVN's ROE is -10.15%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, TRVN is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check NUVL's competition here
TRVN vs TECH Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, TECH has a market cap of 8B. Regarding current trading prices, TRVN is priced at $0.00, while TECH trades at $52.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 72.63. In terms of profitability, TRVN's ROE is -10.15%, compared to TECH's ROE of +0.05%. Regarding short-term risk, TRVN is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check TECH's competition here
TRVN vs PRAX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, PRAX has a market cap of 7.5B. Regarding current trading prices, TRVN is priced at $0.00, while PRAX trades at $339.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas PRAX's P/E ratio is -26.36. In terms of profitability, TRVN's ROE is -10.15%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, TRVN is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check PRAX's competition here
TRVN vs MTSR Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, TRVN is priced at $0.00, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -23.58. In terms of profitability, TRVN's ROE is -10.15%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, TRVN is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check MTSR's competition here
TRVN vs PCVX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, PCVX has a market cap of 7.4B. Regarding current trading prices, TRVN is priced at $0.00, while PCVX trades at $50.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -7.41. In terms of profitability, TRVN's ROE is -10.15%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, TRVN is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check PCVX's competition here
TRVN vs CORT Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, CORT has a market cap of 7.3B. Regarding current trading prices, TRVN is priced at $0.00, while CORT trades at $69.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 195.37. In terms of profitability, TRVN's ROE is -10.15%, compared to CORT's ROE of +0.08%. Regarding short-term risk, TRVN is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check CORT's competition here
TRVN vs IMVT Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, TRVN is priced at $0.00, while IMVT trades at $33.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -12.09. In terms of profitability, TRVN's ROE is -10.15%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, TRVN is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check IMVT's competition here
TRVN vs MRUS Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, TRVN is priced at $0.00, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -17.05. In terms of profitability, TRVN's ROE is -10.15%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, TRVN and MRUS have similar daily volatility (0.00).Check MRUS's competition here
TRVN vs ACLX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, TRVN is priced at $0.00, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -28.27. In terms of profitability, TRVN's ROE is -10.15%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, TRVN is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check ACLX's competition here
TRVN vs KYMR Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, KYMR has a market cap of 6.7B. Regarding current trading prices, TRVN is priced at $0.00, while KYMR trades at $81.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -22.20. In terms of profitability, TRVN's ROE is -10.15%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, TRVN is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check KYMR's competition here
TRVN vs ALKS Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, ALKS has a market cap of 6.7B. Regarding current trading prices, TRVN is priced at $0.00, while ALKS trades at $42.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 44.38. In terms of profitability, TRVN's ROE is -10.15%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, TRVN is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check ALKS's competition here
TRVN vs RETA Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, TRVN is priced at $0.00, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, TRVN's ROE is -10.15%, compared to RETA's ROE of +0.47%. Regarding short-term risk, TRVN is less volatile compared to RETA. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check RETA's competition here
TRVN vs PTGX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, PTGX has a market cap of 6.5B. Regarding current trading prices, TRVN is priced at $0.00, while PTGX trades at $99.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is -55.48. In terms of profitability, TRVN's ROE is -10.15%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, TRVN is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check PTGX's competition here
TRVN vs CELC Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, CELC has a market cap of 6.4B. Regarding current trading prices, TRVN is priced at $0.00, while CELC trades at $132.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas CELC's P/E ratio is -33.57. In terms of profitability, TRVN's ROE is -10.15%, compared to CELC's ROE of -2.45%. Regarding short-term risk, TRVN is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check CELC's competition here
TRVN vs RYTM Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, TRVN is priced at $0.00, while RYTM trades at $91.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -29.71. In terms of profitability, TRVN's ROE is -10.15%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, TRVN is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check RYTM's competition here
TRVN vs CNTA Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, TRVN is priced at $0.00, while CNTA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas CNTA's P/E ratio is -22.37. In terms of profitability, TRVN's ROE is -10.15%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, TRVN is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check CNTA's competition here
TRVN vs COGT Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, COGT has a market cap of 6B. Regarding current trading prices, TRVN is priced at $0.00, while COGT trades at $35.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas COGT's P/E ratio is -16.30. In terms of profitability, TRVN's ROE is -10.15%, compared to COGT's ROE of -0.83%. Regarding short-term risk, TRVN is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check COGT's competition here
TRVN vs SRRK Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, SRRK has a market cap of 6B. Regarding current trading prices, TRVN is priced at $0.00, while SRRK trades at $49.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -14.44. In terms of profitability, TRVN's ROE is -10.15%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, TRVN is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check SRRK's competition here
TRVN vs TGTX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, TGTX has a market cap of 5.9B. Regarding current trading prices, TRVN is priced at $0.00, while TGTX trades at $38.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 13.57. In terms of profitability, TRVN's ROE is -10.15%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, TRVN is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check TGTX's competition here
TRVN vs BLTE Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, TRVN is priced at $0.00, while BLTE trades at $143.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -58.27. In terms of profitability, TRVN's ROE is -10.15%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, TRVN is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check BLTE's competition here
TRVN vs PTCT Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, TRVN is priced at $0.00, while PTCT trades at $73.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is -27.97. In terms of profitability, TRVN's ROE is -10.15%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, TRVN is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check PTCT's competition here
TRVN vs CDTX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, TRVN is priced at $0.00, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas CDTX's P/E ratio is -19.77. In terms of profitability, TRVN's ROE is -10.15%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, TRVN and CDTX have similar daily volatility (0.00).Check CDTX's competition here
TRVN vs ABCM Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, TRVN is priced at $0.00, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, TRVN's ROE is -10.15%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, TRVN is less volatile compared to ABCM. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check ABCM's competition here
TRVN vs LQDA Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, LQDA has a market cap of 5.5B. Regarding current trading prices, TRVN is priced at $0.00, while LQDA trades at $61.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is 364.88. In terms of profitability, TRVN's ROE is -10.15%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, TRVN is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check LQDA's competition here
TRVN vs ISEE Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, TRVN is priced at $0.00, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, TRVN's ROE is -10.15%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, TRVN is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check ISEE's competition here
TRVN vs CRSP Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, TRVN is priced at $0.00, while CRSP trades at $55.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -9.14. In terms of profitability, TRVN's ROE is -10.15%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, TRVN is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check CRSP's competition here
TRVN vs CGON Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, CGON has a market cap of 5.4B. Regarding current trading prices, TRVN is priced at $0.00, while CGON trades at $61.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -25.95. In terms of profitability, TRVN's ROE is -10.15%, compared to CGON's ROE of -0.23%. Regarding short-term risk, TRVN is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check CGON's competition here
TRVN vs APLS Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, TRVN is priced at $0.00, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas APLS's P/E ratio is 38.35. In terms of profitability, TRVN's ROE is -10.15%, compared to APLS's ROE of +0.40%. Regarding short-term risk, TRVN is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check APLS's competition here
TRVN vs LEGN Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, LEGN has a market cap of 5.2B. Regarding current trading prices, TRVN is priced at $0.00, while LEGN trades at $27.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -20.48. In terms of profitability, TRVN's ROE is -10.15%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, TRVN is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check LEGN's competition here
TRVN vs FBIOX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, TRVN is priced at $0.00, while FBIOX trades at $25.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas FBIOX's P/E ratio is N/A. In terms of profitability, TRVN's ROE is -10.15%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, TRVN and FBIOX have similar daily volatility (0.00).Check FBIOX's competition here
TRVN vs MIRM Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, MIRM has a market cap of 5B. Regarding current trading prices, TRVN is priced at $0.00, while MIRM trades at $101.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -7.32. In terms of profitability, TRVN's ROE is -10.15%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, TRVN is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check MIRM's competition here
TRVN vs APGE Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, APGE has a market cap of 4.8B. Regarding current trading prices, TRVN is priced at $0.00, while APGE trades at $80.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -17.97. In terms of profitability, TRVN's ROE is -10.15%, compared to APGE's ROE of -0.33%. Regarding short-term risk, TRVN is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check APGE's competition here
TRVN vs TERN Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, TRVN is priced at $0.00, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas TERN's P/E ratio is -51.41. In terms of profitability, TRVN's ROE is -10.15%, compared to TERN's ROE of -0.20%. Regarding short-term risk, TRVN is less volatile compared to TERN. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check TERN's competition here
TRVN vs CAI Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, TRVN is priced at $0.00, while CAI trades at $16.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas CAI's P/E ratio is -6.04. In terms of profitability, TRVN's ROE is -10.15%, compared to CAI's ROE of +0.06%. Regarding short-term risk, TRVN is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check CAI's competition here
TRVN vs LGND Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, LGND has a market cap of 4.7B. Regarding current trading prices, TRVN is priced at $0.00, while LGND trades at $232.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas LGND's P/E ratio is 30.59. In terms of profitability, TRVN's ROE is -10.15%, compared to LGND's ROE of +0.16%. Regarding short-term risk, TRVN is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check LGND's competition here
TRVN vs FOLD Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, TRVN is priced at $0.00, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -161.00. In terms of profitability, TRVN's ROE is -10.15%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, TRVN and FOLD have similar daily volatility (0.00).Check FOLD's competition here
TRVN vs AKRO Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, TRVN is priced at $0.00, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.57. In terms of profitability, TRVN's ROE is -10.15%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, TRVN is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check AKRO's competition here
TRVN vs ALPN Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, TRVN is priced at $0.00, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, TRVN's ROE is -10.15%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, TRVN is less volatile compared to ALPN. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check ALPN's competition here
TRVN vs TVTX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, TVTX has a market cap of 4.4B. Regarding current trading prices, TRVN is priced at $0.00, while TVTX trades at $47.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas TVTX's P/E ratio is -95.52. In terms of profitability, TRVN's ROE is -10.15%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, TRVN is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check TVTX's competition here
TRVN vs SYRE Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, TRVN is priced at $0.00, while SYRE trades at $72.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas SYRE's P/E ratio is -34.01. In terms of profitability, TRVN's ROE is -10.15%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, TRVN is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check SYRE's competition here
TRVN vs XENE Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, TRVN is priced at $0.00, while XENE trades at $54.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -11.66. In terms of profitability, TRVN's ROE is -10.15%, compared to XENE's ROE of -0.49%. Regarding short-term risk, TRVN is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check XENE's competition here
TRVN vs MANE Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, TRVN is priced at $0.00, while MANE trades at $97.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas MANE's P/E ratio is -38.86. In terms of profitability, TRVN's ROE is -10.15%, compared to MANE's ROE of -0.95%. Regarding short-term risk, TRVN is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check MANE's competition here
TRVN vs OPT Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, TRVN is priced at $0.00, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, TRVN's ROE is -10.15%, compared to OPT's ROE of +0.88%. Regarding short-term risk, TRVN and OPT have similar daily volatility (0.00).Check OPT's competition here
TRVN vs NAMS Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, NAMS has a market cap of 4.1B. Regarding current trading prices, TRVN is priced at $0.00, while NAMS trades at $33.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -19.90. In terms of profitability, TRVN's ROE is -10.15%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, TRVN is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check NAMS's competition here
TRVN vs MRTX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, TRVN is priced at $0.00, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, TRVN's ROE is -10.15%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, TRVN is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check MRTX's competition here
TRVN vs CPRX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, TRVN is priced at $0.00, while CPRX trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 18.09. In terms of profitability, TRVN's ROE is -10.15%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, TRVN is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check CPRX's competition here
TRVN vs VCYT Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, TRVN is priced at $0.00, while VCYT trades at $47.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas VCYT's P/E ratio is 44.44. In terms of profitability, TRVN's ROE is -10.15%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, TRVN is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check VCYT's competition here
TRVN vs KNSA Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, KNSA has a market cap of 3.8B. Regarding current trading prices, TRVN is priced at $0.00, while KNSA trades at $48.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 55.87. In terms of profitability, TRVN's ROE is -10.15%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, TRVN is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check KNSA's competition here
TRVN vs CRNX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, TRVN is priced at $0.00, while CRNX trades at $35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -7.01. In terms of profitability, TRVN's ROE is -10.15%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, TRVN is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check CRNX's competition here
TRVN vs ERAS Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, ERAS has a market cap of 3.8B. Regarding current trading prices, TRVN is priced at $0.00, while ERAS trades at $12.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas ERAS's P/E ratio is -13.12. In terms of profitability, TRVN's ROE is -10.15%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, TRVN is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check ERAS's competition here
TRVN vs DNTH Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, DNTH has a market cap of 3.8B. Regarding current trading prices, TRVN is priced at $0.00, while DNTH trades at $91.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas DNTH's P/E ratio is -21.48. In terms of profitability, TRVN's ROE is -10.15%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, TRVN is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check DNTH's competition here
TRVN vs RYZB Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, TRVN is priced at $0.00, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, TRVN's ROE is -10.15%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, TRVN is less volatile compared to RYZB. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check RYZB's competition here
TRVN vs VKTX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, TRVN is priced at $0.00, while VKTX trades at $32.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -7.76. In terms of profitability, TRVN's ROE is -10.15%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, TRVN is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check VKTX's competition here
TRVN vs CBAY Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, TRVN is priced at $0.00, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, TRVN's ROE is -10.15%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, TRVN is less volatile compared to CBAY. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check CBAY's competition here
TRVN vs ACAD Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, TRVN is priced at $0.00, while ACAD trades at $21.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 9.79. In terms of profitability, TRVN's ROE is -10.15%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, TRVN is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check ACAD's competition here
TRVN vs EWTX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, TRVN is priced at $0.00, while EWTX trades at $33.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas EWTX's P/E ratio is -20.06. In terms of profitability, TRVN's ROE is -10.15%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, TRVN is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check EWTX's competition here
TRVN vs SWTX Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, TRVN is priced at $0.00, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.78. In terms of profitability, TRVN's ROE is -10.15%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, TRVN and SWTX have similar daily volatility (0.00).Check SWTX's competition here
TRVN vs BEAM Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, BEAM has a market cap of 3.4B. Regarding current trading prices, TRVN is priced at $0.00, while BEAM trades at $33.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas BEAM's P/E ratio is -66.94. In terms of profitability, TRVN's ROE is -10.15%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, TRVN is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check BEAM's competition here
TRVN vs DNLI Comparison May 2026
TRVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRVN stands at 864. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, TRVN is priced at $0.00, while DNLI trades at $21.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRVN currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -7.27. In terms of profitability, TRVN's ROE is -10.15%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, TRVN is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for TRVN.Check DNLI's competition here